Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adjuvant paclitaxel + carboplatin followed by pelvic radiotherapy for uterine serous papillary carcinoma
ACTRN12607000125426Phase 2Completed
- Sponsor
- Queensland Centre for Gynaecological Cancer Research
- Start
- Sep 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Serous endometrial adenocarcinoma, sponsored by Queensland Centre for Gynaecological Cancer Research. Primary endpoints: Safety and efficacy of paclitaxel and carboplatin with or without pelvic radiotherapy and Patterns of recurrence. Started Sep 2004; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Serous endometrial adenocarcinoma
Beyond the preview
Go deeper on ACTRN12607000125426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000125426.